Zymeworks (ZYME) Tops Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 24, 2022 4:15 PM ESTEnrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting. Financial position strengthened and cash runway extended following successful completion of equity offering in January. Announced Chris Astle, PhD as new Chief Financial Officer, with Neil Klompas continuing as Chief Operating Officer. Expected to exceed the previously announced workforce reduction of at least 25% by March 1, 2022, ahead of... More
